Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 73.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,090 shares of the company’s stock after selling 201,787 shares during the quarter. Jane Street Group LLC’s holdings in Maravai LifeSciences were worth $591,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Planning lifted its position in shares of Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock worth $373,000 after purchasing an additional 1,881 shares in the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Maravai LifeSciences by 0.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock valued at $4,320,000 after purchasing an additional 3,725 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Maravai LifeSciences in the second quarter valued at approximately $32,000. Venturi Wealth Management LLC purchased a new position in Maravai LifeSciences in the third quarter valued at approximately $47,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Maravai LifeSciences by 32.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,450 shares of the company’s stock valued at $182,000 after acquiring an additional 6,212 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Ratings Changes

MRVI has been the subject of several research analyst reports. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Wolfe Research began coverage on Maravai LifeSciences in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reduced their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. Finally, Robert W. Baird cut their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $10.28.

Insider Transactions at Maravai LifeSciences

In related news, insider Carl Hull purchased 175,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the acquisition, the insider now directly owns 175,000 shares in the company, valued at $987,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.63% of the company’s stock.

Maravai LifeSciences Stock Up 3.5 %

Shares of NASDAQ:MRVI opened at $5.68 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.28 and a 1 year high of $11.56. The stock has a market capitalization of $1.43 billion, a P/E ratio of -3.46 and a beta of -0.08. The stock has a 50-day simple moving average of $5.80 and a 200-day simple moving average of $7.45.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.